Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federica Matteucci

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|March 6, 2023
Diagnostic effectiveness of [<sup>18</sup>F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective studyGianluca Bottoni, Francesco Fiz, Matteo Puntoni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2024
Correlation of [<sup>68</sup>Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patientsEmilio Francesco Giunta, Paola Caroli, Emanuela Scarpi, et al.
Journal of Medicinal Chemistry|March 29, 2025
New Arylpiperazines as Potent and Selective Dopamine D4 Receptor Ligands Potentially Useful to Treat GlioblastomaFederica Matteucci, Pegi Pavletić, Alessandro Bonifazi, et al.
British Journal of Cancer|August 1, 2021
Circulating androgen receptor gene amplification and resistance to <sup>177</sup>Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trialUgo De Giorgi, Maddalena Sansovini, Stefano Severi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2025
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II studyIrene Marini, Emilio Francesco Giunta, Silvia Nicolini, et al.
British Journal of Cancer|July 17, 2020
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancerVincenza Conteduca, Daniel Wetterskog, Emanuela Scarpi, et al.
Cancers|November 26, 2022
PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective StudySusanna Mattoni, Andrea Farolfi, Fabio Formaggio, et al.
The Oncologist|May 16, 2025
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancerVincenza Conteduca, Emanuela Scarpi, Alice Rossi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 14, 2023
Radioligand therapies in cancer: mapping the educational landscape in EuropeValentina Bugani, Luca Battistelli, Maddalena Sansovini, et al.
International Journal of Cancer|October 4, 2021
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patientsVincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
European Journal of Nuclear Medicine and Molecular Imaging|March 6, 2023
Diagnostic effectiveness of [<sup>18</sup>F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective studyGianluca Bottoni, Francesco Fiz, Matteo Puntoni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2024
Correlation of [<sup>68</sup>Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patientsEmilio Francesco Giunta, Paola Caroli, Emanuela Scarpi, et al.
Journal of Medicinal Chemistry|March 29, 2025
New Arylpiperazines as Potent and Selective Dopamine D4 Receptor Ligands Potentially Useful to Treat GlioblastomaFederica Matteucci, Pegi Pavletić, Alessandro Bonifazi, et al.
British Journal of Cancer|August 1, 2021
Circulating androgen receptor gene amplification and resistance to <sup>177</sup>Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trialUgo De Giorgi, Maddalena Sansovini, Stefano Severi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2025
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II studyIrene Marini, Emilio Francesco Giunta, Silvia Nicolini, et al.
British Journal of Cancer|July 17, 2020
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancerVincenza Conteduca, Daniel Wetterskog, Emanuela Scarpi, et al.
Cancers|November 26, 2022
PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective StudySusanna Mattoni, Andrea Farolfi, Fabio Formaggio, et al.
The Oncologist|May 16, 2025
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancerVincenza Conteduca, Emanuela Scarpi, Alice Rossi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 14, 2023
Radioligand therapies in cancer: mapping the educational landscape in EuropeValentina Bugani, Luca Battistelli, Maddalena Sansovini, et al.
International Journal of Cancer|October 4, 2021
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patientsVincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, et al.
Pageof 8